CHICAGO / BERLIN:The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.
The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop.
Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.
They include messenger RNA (mRNA) technology used by Moderna Inc and Pfizer Inc with partner BioNTech SE, and inactivated cold virus platforms used by Oxford University/AstraZeneca Plc, Johnson & Johnson and CanSino Biologics, whose vaccine has been approved for military use in China.
Merck & Co in September started testing a COVID-19 vaccine based on a weakened measles virus that delivers genes from the new coronavirus into the body to stimulate an immune response to the coronavirus.
Of these, only the technology offered by J&J and CanSino that use cold viruses as vectors to deliver coronavirus genetic material have ever produced a licensed vaccine - for Ebola.
The next set of candidates - with late-stage trial results expected in the first half of 2021 - are heavily skewed toward approaches that have produced successful vaccines.
Conventional methods include using a killed or inactivated version of the pathogen that causes a disease to provoke an immune response, such as those used to make flu, polio and rabies vaccines.
Also more common are protein-based vaccines that use purified pieces of the virus to spur an immune response. Vaccines against whooping cough, or pertussis, and shingles employ this approach.
French drugmaker Sanofi is developing a protein-based COVID-19 vaccine employing the same approach it uses for its Flublok seasonal flu vaccine. Sanofi expects to start the final phase of testing in early December, with approval targeted in the first half of 2021.
While Novavax Inc has not yet produced a licensed vaccine, it is using similar purified protein technology and expects to start a late-stage U.S. trial involving 30,000 volunteers in late November.
"Those are more traditional approaches, so we can feel more comfortable that we have a lot of experience with them," said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia.
Offit also sees promise in some of the inactivated virus vaccines being developed by Chinese researchers, including Sinopharm's China National Biotec Group (CNBG), one of the few first-crop developers using a traditional technique.
Other second-wave developers are making vaccines based on virus-like particles (VLPs), which mimic the structure of the coronavirus but contain no genetic material from it.
VLP vaccines can be produced in a variety of different types of cells, including mammal, bacterial, insect, yeast and plant cells. This approach has been used to develop vaccines for hepatitis B and human papillomavirus.
Quebec's Medicago is testing a VLP COVID-19 vaccine grown in tobacco plants with the backing of tobacco company Philip Morris.
Medicago has yet to produce an approved vaccine, but has completed large-scale testing for a seasonal flu vaccine using this approach. It plans to begin mid-stage trials of its COVID-19 vaccine next month and aims to make up to 1 billion doses a year by 2023.
Others are looking at alternative delivery methods, such as the nasal spray vaccine being developed by a team at Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise, which is based on a modified flu virus.
CHALLENGES AHEAD
The second crop, however, could face problems completing large studies if the current leaders bring their vaccines over the finish line in the coming months.
"If we get a super vaccine in December, from company x, which is on the market, it will be difficult to recruit participants into other studies," said Peter Kremsner from the University Hospital in Tuebingen, Germany.
"Then everyone will say, if the vaccine exists, I will get vaccinated now with this vaccine. This will definitely prove a problem for recruitment,” added Kremsner, who is testing CureVac's mRNA COVID-19 vaccine in early clinical trials with backing from the Bill & Melinda Gates Foundation.
On the flip side, it is easier and faster to prove efficacy when community spread of the virus is rampant as is happening again in the United States, Europe and elsewhere, a potential advantage for companies starting large-scale vaccine trials in the near future.
Reuters
Thu Oct 29 2020
The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. REUTERS file pic
AWANI Pagi: Hari sedunia bagi keselamatan & kesihatan di tempat kerja 2024
Memahami kaitan perubahan iklim kepada isu keselamatan dan kesihatan pekerjaan, yang diangkat sebagai tema Hari Sedunia bagi Keselamatan dan Kesihatan di Tempat Kerja tahun ini. Diskusi bersama Ts Mohd Soffian Osman, Perunding Keselamatan & Kesihatan Awam, Safety Management Academy 7.30 pagi nanti
Jualan kediaman kekal memberangsangkan - TA Global
Kenaikan harga hartanah akibat tekanan inflasi ke atas harga bahan binaan tidak menghalang hasrat rakyat Malaysia untuk memiliki rumah idaman.
Rakyat Israel desak kerajaan bawa pulang tebusan yang tinggal
Ribuan berkumpul di Tel Aviv pada Sabtu malam bagi mendesak kerajaan Israel mencapai perjanjian gencatan senjata dengan Hamas dan membawa pulang tebusan yang tinggal
Hamas keluarkan video dua tebusan Israel
Kumpulan pejuang Hamas mengedarkan video menampilkan dua tahanan Israel yang menyeru kepada Perdana Menteri Israel, Benjamin Netanyahu, untuk memenuhi perjanjian pembebasan mereka.
Israel sedia tangguh serangan ke atas Rafah
Israel bersedia menangguhkan serangan ke Rafah jika perjanjian pembebasan tahanan Hamas tercapai. Menteri Luar Israel, Israel Katz, menegaskan keutamaan pembebasan tahanan.
Restoran nasi kandar dibaling cat, polis kesan tiga lelaki
Cat merah tersebut terkena papan tanda dan pintu hadapan restoran yang mula beroperasi pada Sabtu.
Kawasan Beris Lalang terbakar lagi
Cuaca panas melampau di Kelantan menyebabkan kebakaran ladang dan semak di kawasan Beris Lalang. Penduduk dan pekebun mengalami kerugian
Ringgit dijangka diniaga dalam jajaran kecil
Ringgit Malaysia dijangka berada di sekitar 4.77 berbanding Dolar AS minggu depan, bergantung kepada keputusan FOMC dan data ekonomi AS
Bursa Malaysia dijangka diniagakan dalam jajaran kecil
Analisis terkini menunjukkan Bursa Malaysia berpotensi naik dalam jajaran kecil minggu depan, dengan pandangan positif terhadap kembalinya dana asing. Paras sokongan dan konsolidasi disebutkan.
PM tiba di Riyadh untuk hadiri mesyuarat WEF
Datuk Seri Anwar Ibrahim tiba di Riyadh bagi menghadiri Mesyuarat Khas Forum Ekonomi Sedunia. Beliau dijadual terlibat dalam dialog strategik, panel, dan pertemuan bersama pemimpin serantau
Kelaparan akut jejaskan 281.6 juta orang tahun lepas - PBB
Tahap bahaya kelaparan akut menjejaskan 281.6 juta orang tahun lepas, tahun kelima berturut-turut bahawa ketakjaminan makanan semakin memburuk.
Hamilton optimis kedudukan lebih baik di GP China
Lewis Hamilton melihat potensi kedudukan yang lebih baik dalam saingan Grand Prix yang kembali ke China buat pertama kali dalam tempoh lima tahun, hujung minggu ini.
'Selfish!' - Fasha Sandha sedih raya di Perlis tak jadi gara-gara dijangkiti COVID-19
Fasha berkata dia mula melakukan pemeriksaan COVID-19 selepas berasa tidak sihat badan dan mengalami bersin tidak henti sejak Raya pertama.
Kes COVID-19 catat penurunan ketara pada ME 14/2024 - KKM
Jumlah kes COVID-19 menurun 97.1 peratus kepada 493 kes pada Minggu Epidemiologi ke-14 (ME 14/2024) iaitu bagi tempoh 31 Mac hingga 6 April lepas berbanding 17,256 kes pada ME 1/2024.
China jadikan pengalaman pencegahan COVID-19 untuk hadapi pandemik masa depan
China akan menjadikan pengalaman dalam pencegahan dan kawalan COVID-19 untuk membuat persediaan yang lebih proaktif untuk menghadapi pandemik masa depan seperti "Penyakit X".
Negara berdepan ketirisan subsidi diesel serius - Amir Hamzah
Negara kini sedang berdepan isu ketirisan subsidi diesel yang serius dan wujud kemungkinan terdapat pihak yang tidak layak masih menikmati subsidi itu, kata Menteri Kewangan II Datuk Seri Amir Hamzah.
Kematian akibat kemalangan jalan raya lebih tinggi daripada COVID-19 - Anthony Loke
PDRM akan mengeluarkan data mengenai kemalangan jalan raya pada setiap hari, bukan setahun sekali seperti diamalkan sebelum ini.
Ismail Sabri ziarah lapan beradik yatim piatu akibat COVID-19
Ismail Sabri tiba kira-kira jam 2 petang di kediaman lapan beradik itu di Taman Adenium, Bukit Beruntung pada Selasa.
Teori konspirasi 'Penyakit X'
Ahli teori konspirasi AS sekali lagi membuat 'keuntungan' selepas PBB memberi amaran tentang wabak lebih berbahaya iaitu 'Penyakit X'.
Reformasi dasar, kukuhkan perlindungan, produktiviti pekerja tidak formal
Reformasi dasar perlu dilakukan dalam usaha meningkatkan perlindungan dan produktiviti pekerja tidak formal di Malaysia.